Skip to content
value.today

Triangle Therapeutics Inc.

🇺🇸 Los Angeles, California, USAPharmaceuticalsFounded 2013

Formerly Triangle Pharmaceuticals Inc.

Total raised
$34 M
6 rounds on record
Latest round
$4 M
Jun 2021
First round on record
Apr 2015
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Triangle Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2021$4 MNo. 6$2 to $10 million

Triangle Therapeutics Inc.: Raise no. 6, Jun 2021

Investors in this round

38 investors had bought by the notice of May 17, 2022: 38 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carl W. McKinzie · Executive Officer, Director
  • Jean B. deKernion · Executive Officer, Director
  • Kenneth A. Schultz, M.D. · Executive Officer, Director
  • Louis L. Gonda · Director
  • Timothy B. Donahue, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kenneth A. Schultz, M.D., Ceo. Source: SEC Form D, newest notice filed May 17, 2022. Read the notice at the SEC.

equity, optionsSEC
Feb 2020$3 MNo. 5$2 to $10 million

Triangle Therapeutics Inc.: Raise no. 5, Feb 2020

Investors in this round

25 investors had bought by the notice of Feb 24, 2021: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carl W. McKinzie · Executive Officer, Director
  • Jean B. deKernion · Executive Officer, Director
  • Kenneth A. Schultz, M.D. · Executive Officer, Director
  • Louis L. Gonda · Director
  • Timothy L. Donahue, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kenneth A. Schultz, M.D., Ceo. Source: SEC Form D, newest notice filed Feb 24, 2021. Read the notice at the SEC.

equity, optionsSEC
Mar 2019$8 MNo. 4$2 to $10 million

Triangle Therapeutics Inc.: Raise no. 4, Mar 2019

Investors in this round

28 investors had bought by the notice of Mar 11, 2019: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carl W. McKinzie · Executive Officer, Director
  • Jean B. deKernion · Executive Officer, Director
  • Kenneth A. Schultz, M.D. · Executive Officer, Director
  • Lynne W. Rollins · Executive Officer
  • Louis L. Gonda · Director
  • Timothy L. Donahue, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Lynne Rollins, Cfo. Source: SEC Form D, newest notice filed Mar 11, 2019. Read the notice at the SEC.

equity, optionsSEC
Feb 2017$4 MNo. 3$2 to $10 million

Triangle Therapeutics Inc.: Raise no. 3, Feb 2017

Investors in this round

19 investors had bought by the notice of Mar 7, 2017: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carl W. McKinzie · Executive Officer, Director
  • Johanna Holldack · Executive Officer, Director
  • Lynne W. Rollins · Executive Officer
  • Nathan W. Mata · Executive Officer
  • Jean B. deKernion · Director
  • Louis L. Gonda · Director
  • Owen L. Witte, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “This amount includes convertible promissory notes, warrants to purchase preferred stock, the preferred stock issuable upon exercise of the warrants and common stock issuable upon conversion thereof.”

Signed by Lynne Rollins, Cfo. Source: SEC Form D, newest notice filed Mar 7, 2017. Read the notice at the SEC.

equity, optionsSEC
Feb 2016$10 MNo. 2$10 to $50 million

Triangle Therapeutics Inc.: Raise no. 2, Feb 2016

Investors in this round

43 investors had bought by the notice of Oct 20, 2016: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $20 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carl W. McKinzie · Executive Officer, Director
  • Johanna Holldack · Executive Officer, Director
  • Lynne W. Rollins · Executive Officer
  • Nathan W. Mata · Executive Officer
  • Caius B. Radu · Director
  • Jean B. deKernion · Director
  • Johannes Czernin · Director
  • Louis L. Gonda · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “This amount includes preferred stock, common stock, warrants and common stock issuable upon conversion of preferred stock/exercise of warrants.”

Signed by Johanna Holldack, M.D., President and CEO. Source: SEC Form D and 1 amendment, newest notice filed Oct 20, 2016. Read the notice at the SEC.

equity, optionsSEC
Apr 2015$5 MNo. 1$2 to $10 million

Triangle Therapeutics Inc.: Raise no. 1, Apr 2015

Investors in this round

26 investors had bought by the notice of Jul 2, 2015: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $6 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Carl McKinzie · Executive Officer, Director
  • Caius L. Radu · Director
  • Jean L. deKernion · Director
  • Johannes L. Czernin · Director
  • Louis L. Gonda · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Estimated”

Signed by Carl McKinzie, President. Source: SEC Form D, newest notice filed Jul 2, 2015. Read the notice at the SEC.

equity, debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Triangle Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (May 2022).

    SEC Form D · May 2022

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · May 2022

That is all the official record says: Triangle Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Triangle Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 43 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Triangle Therapeutics Inc.
NameRoleNamed in
Carl W. McKinzieExecutive officerMay 2022
Jean B. deKernionExecutive officerMay 2022
Kenneth A. Schultz, M.D.Executive officerMay 2022
Lynne W. RollinsExecutive officerMar 2019
Johanna HolldackExecutive officerMar 2017
Nathan W. MataExecutive officerMar 2017
John W. StrettonExecutive officerFeb 2016
Carl McKinzieExecutive officerJul 2015
Carl W. McKinzieDirectorMay 2022
Jean B. deKernionDirectorMay 2022
Kenneth A. Schultz, M.D.DirectorMay 2022
Louis L. GondaDirectorMay 2022
Timothy B. Donahue, M.D.DirectorMay 2022
Timothy L. Donahue, M.D.DirectorFeb 2021
Johanna HolldackDirectorMar 2017
Owen L. Witte, M.D.DirectorMar 2017
Caius B. RaduDirectorOct 2016
Johannes CzerninDirectorOct 2016
Caius L. RaduDirectorJul 2015
Carl McKinzieDirectorJul 2015
Jean L. deKernionDirectorJul 2015
Johannes L. CzerninDirectorJul 2015